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Purpose: Using an established rabbit toxicological model, this in vivo study compared the ocular cytotoxicity of four
topical intraocular pressure (IOP)-lowering agents: the commercial benzalkonium chloride (BAC)-containing solutions
of  0.005%  latanoprost,  0.004%  travoprost,  0.03%  bimatoprost  (containing  0.02%,  0.015%,  and  0.005%  BAC,
respectively), and 0.005% latanoprost in a new cationic emulsion (LCEm) formulation.
Methods: Thirty adult male New Zealand albino rabbits were used in this study. They were randomly divided into five
groups: 50 µl of sterile phosphate-buffered saline (PBS) along with each formulation was applied onto rabbit eyes 15
times at 5 min intervals. The ocular surface changes were investigated using slit-lamp examination, corneal in vivo confocal
microscopy (IVCM) for cornea, limbus, conjunctiva/conjunctiva-associated lymphoid tissue (CALT) investigations, and
conjunctival imprints for cytology and flow cytometry (FCM) analyses.
Results: Antiglaucoma eye drops induced an ocular surface cytotoxicity primarily related to the concentration of their
common BAC preservative (0.02%BAC+latanoprost> 0.015%BAC+travoprost> 0.005%BAC+bimatoprost). LCEm did not induce any
obvious signs of toxicity on the rabbit ocular surface with results similar to those of PBS; moreover, the conjunctiva/
CALT and cornea had almost normal aspects.
Conclusions: These in vivo and ex vivo toxicological procedures performed in an acute stress model confirmed the ocular
surface cytotoxicity of BAC-containing antiglaucomatous eye drop solutions. The new formulation, LCEm, was well
tolerated without inducing ocular surface damage or CALT activation. The cationic emulsion of latanoprost will most
likely have fewer long-term adverse effects on the ocular surface than formulations containing toxic preservative BAC
and may improve long-term tolerance over BAC-containing antiglaucomatous topical treatments.
Glaucoma remains the second leading cause of blindness
in  the  world  [1],  and  an  estimated  60.5  million  people
worldwide  will  be  affected  by  open-angle  glaucoma  and
angle-closure glaucoma in 2010, increasing to 79.6 million by
2020 [2]. While the efficacy of a neuroprotective strategy
remains unclear, it has been shown that intraocular pressure
(IOP)-lowering agents, such as prostaglandin (PG) analogues,
play a major role in glaucoma treatment [3].
Today, long-term antiglaucoma eye drop therapy requires
not only efficacy and safety, but also good tolerability for
improved  patient  comfort,  and  hence  better  compliance.
However,  the  toxic  preservative  benzalkonium  chloride
(BAC) is still an important excipient found in the vast majority
of  PG  eye  drop  formulations.  BAC  is  a  mixture  of
alkylbenzyldimethylammonium    chlorides    used   for   the
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bactericidal and microbicidal activity of its C12 and C14 alkyl
derivatives [4]. Numerous in vitro and ex vivo studies have
reported cytotoxic effects of the major IOP-lowering agents
containing  BAC  [5-9].  For  example,  BAC-containing
latanoprost  (BAC+latanoprost)  and  timolol  (BAC+timolol)  eye
drops  exhibited  higher  proinflammatory  and  proapoptotic
effects on conjunctival cells than did BAC-free timolol (BAC-
timolol)  eye  drops  [9].  In  rat  corneal  and  conjunctival
epithelial cells, stress-related genes (c-fos and c-jun) were
transcriptionally  activated  and  the  cyclooxygenase-2
(COX-2)  gene  was  overexpressed  after  BAC-containing
antiglaucoma  medications,  such  as  BAC+timolol,  BAC
+latanoprost, or BAC+isopropyl unoprostone treatment [10].
Nowadays,  the  ocular  cytotoxicity  of  antiglaucoma
treatment can be greatly reduced by the use of preservative-
free single-dose units, such as carteolol [11] or tafluprost
[12,13], and preserved BAC-free multi-dose systems, such as
the ABAK system available for nonpreserved beta-blockers,
or self-preserved ionic-buffered system (e.g., sofZia®) found
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1690in Travatan Z® solution. Compared to BAC-preserved eye
drops,  preservative-free  eye  drops  consistently  induced
significantly fewer ocular symptoms and signs of irritation in
patients, such as pain or discomfort, foreign body sensation,
stinging or burning, and dry eye sensation [14]. Many in vitro
or ex vivo studies were conducted to demonstrate their good
tolerance  [6,9,12].  Cationic  micro-emulsions  are  another
interesting approach, offering a new way to deliver lipophilic
drugs to the ocular surface [15-17]. These cationic emulsions,
through the electrostatic attraction of their positively charged
oil droplets with the highly negatively charged ocular surface
mucins,  have  an  increased  ocular  surface  residence  time,
hence  improving  the  absorption  of  the  active  ingredient
loaded  in  the  emulsion.  This  new  technology  has  been
successfully  developed  for  the  treatment  of  mild  dry  eye
symptoms (Cationorm®) [18,19]. This very similar cationic
emulsion used as a carrier for cyclosporine A has entered a
phase II clinical trial in the United States and a phase III
clinical trial in Europe for the treatment of Sjögren's syndrome
and  vernal  keratoconjunctivitis,  respectively  [20,21].  In  a
previous  animal  study  [19],  we  demonstrated  that
nonpreserved  cationic  emulsion  vehicles  are  very  well
tolerated by the ocular surface and induced no cytotoxicity,
even after repeated applications [19]. This interesting new
technology  can  also  be  used  for  the  efficient  delivery  of
antiglaucoma  PG  analogues.  Moreover,  as  these  cationic
emulsions are devoid of any preservative effect, they  have a 
better  ocular  surface  tolerance  than  standard PG analogue 
formulations, as a result of BAC removal.
The aim of this in vivo study was to assess the ocular
tolerance  of  the  prostaglandin  analogue  latanoprost,  in  a
newly developed cationic emulsion formulation (LCEm), and
to  compare  it  with  more  classic  BAC-containing
antiglaucoma  eye  drops:  0.02%BAC+latanoprost,  0.015%BAC
+travoprost,  and  0.005%BAC+bimatoprost.  In  this  study,  we
compared these PGs using clinical observations, analyses of
microstructures  of  the  ocular  surface  by  in  vivo  confocal
microscopy (IVCM), and impression cytology (IC). None of
these in vivo and ex vivo methods involved animal sacrifice,
and  they  provided  standardized  cell-level  analyses  by
quantified  systems.  In  addition,  we  were  particularly
interested  in  investigating  the  conjunctiva-associated
lymphoid tissue (CALT), a structure that plays an important
role  in  the  innate  and  acquired  ocular  surface  immunity.
Careful  analysis  of  the  inflammatory  markers  within  the
CALT allowed us to precisely discriminate the different PG-
containing  antiglaucoma  eye  drops  with  regard  to  their
specific ocular toxicity.
METHODS
Animals: All experiments were conducted in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. Thirty male New Zealand white (NZW)
rabbits were randomly divided into five groups: each group
consisted  of  six  rabbits  for  clinical  evaluation,  IVCM
observation, and conjunctival imprint collection at the time
points of 4 h (H) and 1 day (D; three rabbits for H4 and three
for D1). The time points were chosen according to a previous
study [19].
Antiglaucoma  eye  drop  treatments:  Fifty  microliters  of
treatment preparation was instilled according to a previous
toxic model [19,22]: sterile phosphate-buffered saline (PBS),
three commercial solutions of 0.005% latanoprost containing
0.02%  BAC  (Xalatan®;  Pfizer,  New  York,  NY),  0.004%
travoprost containing 0.015% BAC (Travatan®; Alcon, Fort
Worth, TX), 0.003% bimatoprost containing 0.005% BAC
(Lumigan®; Allergan, Irvine, CA), and a new formulation of
0.005% latanoprost in a cationic emulsion (LCEm; Novagali
Pharma, Evry, France). The LCEm was nonpreserved with
physiological  pH  and  osmolality,  and  contained  0.002%
cetalkonium chloride (CKC) acting as a cationic agent. In this
model of acute toxicological stress, each solution was applied
onto the ocular surface 15 times, at 5 min intervals, with a
sterile micropipette.
Clinical findings and Draize test: The first instillation was
chosen  as  time  zero  (T0).  At  H4  and  D1  the  eyes  were
examined  using  a  slit-lamp.  Ocular  irritation  was  scored
according to a modified Draize test [19].
In vivo confocal microscopy observation and new IVCM-
CALT  scale:  A  laser-scanning  IVCM  Heidelberg  Retina
Tomograph  (HRT)  II/  Rostock  Cornea  Module  (RCM;
Heidelberg Engineering GmbH, Heidelberg, Germany) was
used to examine the entire ocular surface (cornea/conjunctiva/
limbus) as previously described [19]. An IVCM scale system
was used as in a previous study [13].
The  CALT  structure  was  examined  as  previously
described by our team [23]. Based on the published IVCM
scale [13,24], we developed a new IVCM scale including the
CALT structure description in order to quantify the ocular
surface reactions more extensively (Table 1). We especially
took into account the levels of inflammatory cell infiltration
at the periphery (outside) and in the center (inside) of the
CALT follicles. We scored up to four levels of inflammatory
cell infiltration: (0/1); no or very slight infiltration (0–100
inflammatory  cells/mm2),  (2);  moderate  (100–500
inflammatory  cells/mm2),  (3);  pronounced  (500–1000
inflammatory  cells/mm2),  and  (4);  severe  (>1000
inflammatory cells/mm2).
Conjunctival impression cytology analysis for cytology and
flow  cytometry  analyses:  Impression  cytology  specimens
were collected from the superior conjunctiva using techniques
previously described [19]. Two types of filter paper were
used:  two  nitrocellulose  membranes  (Millipore,  Bedford,
MA) were applied to the superior bulbar conjunctiva for cresyl
violet cytology (1%, number 5235; Merck, Fontenay-sous-
Bois,  France),  and  two  polyether  sulfone  membranes
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for flow cytometry (FCM) procedures.
For  the  cresyl  violet  staining,  cellular  damage  and
inflammatory cell infiltration were quantified according to a
published IC score system [25]. Conjunctival cells were also
extracted  and  analyzed  using  FCM  (FC500;  Beckman
Coulter,  Miami,  FL).  Indirect  immunofluorescence
procedures were used for CD45-positive hematopoietic cell
staining (1:50; MCA808G; Serotec AbD, MorphoSys, UK),
and the results were expressed as percentages of positive cells.
After the FCM analysis, the cell suspension was stained with
propidium iodide (PI 0.5 µg/ml; Sigma Chemical Company,
St. Louis, MO), and was spun down on a glass slide using a
cytospin centrifuge (Shandon Cytospin 4; Thermo, Electron
Corporation,  Waltham,  MA)  for  analysis  with  a  confocal
microscope (E800; PCM 2000; Nikon, Tokyo, Japan).
Statistical  analysis:  All  statistical  comparisons  were
performed  with  two-way  analysis  of  variance  (ANOVA),
followed by multiple pair-wise comparisons using Fisher’s
method adjustment (Statview V for Windows; SAS Institute,
Cary, NC).
RESULTS
Clinical observation and Draize test: After instillations, all
three BAC-containing PGs induced an obvious ocular surface
toxicity  in  rabbits:  BAC+latanoprost  (Figure  1A)  and  BAC
+travoprost  (Figure  1B)  induced  obvious  hyperemia,
chemosis, and purulent secretions;  BAC+bimatoprost (Figure
1C) induced mild hyperemia but with no secretions. PBS
(Figure 1D) presented a normal ocular surface aspect, while
LCEm (Figure 1E) presented only slight hyperemia.
At H4, the BAC+latanoprost-treated animals had the highest
Draize score compared to all other groups (p<0.01 versus BAC
+travoprost, and p<0.0001 versus the remaining three groups;
Figure 1F). BAC+Travoprost-treated rabbits had higher Draize
scores than those treated with BAC+bimatoprost, PBS, or LCEm
(p<0.001 for three groups), without any differences among the
last  three  groups.  At  D1,  the  Draize  score  for  the  BAC
+latanoprost  group  remained  the  highest  (p<0.01  when
compared with BAC+bimatoprost, PBS and LCEm groups). At
D1, in the BAC+travoprost group, the treated eyes had not yet
returned to their normal aspect, but there were no statistical
differences when compared with the other groups (p>0.05).
The BAC+bimatoprost, PBS, and LCEm groups all presented
normal aspects at D1.
IVCM images and two IVCM scale analyses:
Superficial epithelium—At H4, BAC+latanoprost (Figure
2A; line 1) and BAC+travoprost-treated eyes (Figure 2B; line 1)
displayed various abnormalities of the corneal epithelium,
including  partial  desquamation,  irregular  cell  shapes,
abnormal reflectivity patterns, swollen cells, and occasional
inflammatory cell infiltration.  BAC+Bimatoprost (Figure 2C;
line 1) did not induce such major changes, with only rare
irregular  cell  shapes  observed.  PBS-  and  LCEm-instilled
(Figure  2D,E;  line  1)  rabbits  presented  eyes  with  normal
aspects.
Basal epithelium—BAC+latanoprost (Figure 2A; line 2),
BAC+travoprost  (Figure  2B;  line  2),  and  BAC+bimatoprost
(Figure 2C; line 2) all induced inflammatory cell infiltration
at levels related to their concentrations of the preservative
BAC: 126.50±16.89 cells/mm2 for  BAC+latanoprost (p<0.01
when compared with all the other groups); 89.70±10.72 cells/
mm2 for BAC+travoprost (p<0.01 when compared with the other
groups);  and  21.40±3.11  cells/mm2  for  BAC+bimatoprost.
PBS and LCEm (Figure 2D,E; line 2) did not induce any
inflammation (<5 cells/mm2) during the entire observation
time.
Limbus—For the BAC+latanoprost group (Figure 2A; line
3), obvious inflammatory cell infiltration was noted in the
peripheral cornea and limbus area. No obvious reactions were
seen in the other groups.
Conjunctival blood vessels—For all BAC-containing
PG-treated groups (Figure 2A,B,C; line 4),  a phenomenon of
inflammatory cell rolling was noted, as characteristic cells
fixed alongside the blood vessel wall were observed. The PBS
TABLE 1. IN VIVO CONFOCAL MICROSCOPY SCORING FOR THE EVALUATION OF OCULAR TOXICITY IN CALT ANALYSIS.
CALT reactivity is evaluated in two different areas: inside and outside the follicle





For IVCM-CALT analysis, we took into account the level of inflammatory cell infiltration at the periphery (outside) and in the
center  (inside) of the superficial layers in CALT follicles: (0/1): no or very slight infiltration (0–100 inflammatory cells/mm2);
(2): moderate (100–500 inflammatory cells/mm2); (3): pronounced (500–1000 inflammatory cells/mm2), (4): severe (>1000
inflammatory cells/mm2).
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1692and LCEm groups (Figure 2D,E; line 4) did not induce such
obvious rolling of inflammatory cells.
IVCM scale—The whole ocular surface cytotoxicity was
scored by using the IVCM scale (Figure 2F). At H4, treatment
with BAC+latanoprost and BAC+travoprost eye drops induced the
highest IVCM scores when compared with the other groups
(p<0.002  for  both).  BAC+Bimatoprost  induced  moderate
toxicity  by  IVCM  analysis,  which  was  lower  than  BAC
+latanoprost and BAC+travoprost (p<0.002), but still higher than
PBS and LCEm (p<0.05). The LCEm-treated group was not
statistically different from the PBS-instilled group. At D1, the
IVCM  score  remained  very  high  after  BAC+latanoprost
application  (p<0.002  when  compared  with  the  four  other
groups). In contrast, the IVCM scores of the other four groups
decreased, with no statistical difference among them at D1
(p>0.1).
Conjunctiva-associated  lymphoid  tissue—Figure  3
shows representative IVCM images of the superficial layers
of CALT follicles at H4. Following the instillation of  BAC
+latanoprost  and  BAC+travoprost  eye  drops,  severe
inflammatory cell infiltration was observed, especially in the
follicle and parafollicular areas. This infiltration consisted of
numerous  hyper-reflective  patterns  in  the  BAC+latanoprost
(Fig.  3A)  and  BAC+travoprost  (Figure  3B)  groups
Figure 1. Microphotographs of typical
clinical features after 15 instillations of
different prostaglandins and Draize test
evaluation at 4 h. Microphotographs of
typical  clinical  features  of  instilled
rabbit eyes at H4 for  BAC+latanoprost-
(A),  BAC+travoprost-  (B),  BAC
+bimatoprost-  (C),  PBS-  (D),  and
latanoprost  in  cationic  emulsion
(LCEm)-treated  groups  (E).  BAC
+Latanoprost  and  BAC+travoprost
induced  diffuse  hyperemia,  chemosis,
and  purulent  secretions  on  the  ocular
surface.  BAC+Bimatoprost also induced
mild  conjunctiva  hyperemia.  LCEm-
receiving  eyes  only  presented  slight
hyperemia. Bar chart of ocular irritation
evaluations using a modified Draize test
scale (F) at H4 and D1. The asterisk
indicates a p<0.0001 compared with the
BAC+latanoprost-instilled  group.  The
double  asterisk  indicates  a  p<0.01
compared  with  the  BAC+latanoprost-
instilled  group,  and  the  sharp  (hash
mark)  indicates  a  p<0.001  compared
with the BAC+travoprost-instilled group.
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1693corresponding  to  polymononuclear  leukocytes  (PMNs),
lymphocytes, and dendritiform cells as demonstrated by a
previous  immunohistology  study  [23].  Application  of
bimatoprost eye drops (Figure 3C) containing 0.005% BAC
also  induced  a  moderate  infiltration  of  hyper-reflective
inflammatory cells around the CALT follicle. In contrast,
instillation of PBS (Figure 3D) did not induce active changes
in the CALT structure. Similarly, when LCEm was instilled
onto  the  ocular  surface,  no  special  activation  was  found
(Figure  3E).  The  inflammatory  cell  infiltration  decreased
dramatically but still persisted at D1 for three BAC-containing
groups (data not shown).
New  IVCM  scale  including  CALT  analysis—To
increase the resolution power of the IVCM, we decided to
include the CALT activation data into the aforementioned
IVCM scale, and create a new IVCM scale (IVCM + CALT).
This new IVCM scale follows the same trend as our previously
published IVCM scale (Figure 3F). At H4, the BAC+latanoprost
and BAC+travoprost groups had higher toxicity scores than the
other three groups (p<0.0001 for BAC+latanoprost, p<0.0002
for BAC+travoprost). BAC+Bimatoprost also induced a moderate
toxic score, which was lower than two other BAC-containing
eye drops but still higher than PBS and LCEm groups. The
LCEm  group  scores  still  showed  no  significant  statistical
difference  to  the  scores  from  the  PBS  group.  At  D1,  BAC
Figure 2. IVCM images of rabbit ocular
surface  (cornea,  limbus,  and
conjunctiva).  IVCM  images  of  rabbit
ocular  surface  at  H4  after  BAC
+latanoprost  (A),  BAC+travoprost  (B),
BAC+bimatoprost  (C),  PBS  (D),  and
LCEm  (E)  instillations,  of  the
superficial epithelium (line 1), the basal
epithelium (line 2: 10–15 μm from the
superficial epithelium layer), the limbus
(line  3:  about  20–30  μm  from  the
superficial  epithelium  layer),  and  the
conjunctival substantia propria (line 4:
50–80  μm  from  the  superficial
epithelium layer). BAC+Latanoprost and
BAC+travoprost-treated eyes showed the
greatest damage in the epithelium and
the  greatest  inflammatory  cell
infiltration in the basal epithelium and
limbus. BAC+Bimatoprost induced slight
inflammation  in  the  basal  epithelium.
These three BAC-containing eye drops
induced  inflammatory  cells  rolling  in
conjunctival  blood  vessels.  PBS  and
LECm  did  not  induce  any  obvious
ocular surface microstructure damage.
The scale bar indicates 100 μm. IVCM
scores (F) for the five tested groups. BAC
+Latanoprost  and  BAC+travoprost
presented the highest IVCM toxic score
at H4 and D1, with intermediate results
for  BAC+bimatoprost.  The  toxicity  of
LECm was less than that of the three
BAC-containing  commercial
prostaglandins  with  no  significant
difference with the PBS group at all time
points. The asterisk indicates a p<0.002
compared  with  BAC+latanoprost.  The
sharp  indicates  a  p<0.002  compared
with  BAC+travoprost  and  the  filled
diamond indicates a p<0.05 compared
with BAC+bimatoprost.
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1694+latanoprost-treated rabbits still had the highest IVCM score
(p<0.003  when  compared  with  BAC+travoprost-  and  BAC
+bimatoprost-treated groups; p<0.0001 when compared with
the PBS and LCEm groups). The scores decreased in the other
four groups between H4 and D1, and presented no statistical
differences among them.
IC  staining,  IC  score  and  FCM  analysis:  Significant
infiltration  of  inflammatory  cells  was  observed  after  the
instillation of BAC+latanoprost (Figure 4A, red circles) with rare
and  altered  conjunctival  epithelial  cells  that  presented
significant anisocytosis and anisonucleocytosis. No goblet
cells  were  seen.  Following  instillations  of  BAC+travoprost
(Figure 4B), numerous inflammatory cell islets, principally
comprising  PMNs  with  their  characteristic  multilobulated
nucleus,  were  observed.  Rare  goblet  cells  could  also  be
observed. BAC+Bimatoprost (Figure 4C) instillations induced
slight anisocytosis in the epithelium with cells having normal
nuclei. Some infiltration of inflammatory cells could also be
observed, but without the formation of obvious inflammatory
cell  islets.  The  number  and  morphology  of  goblet  cells
remained normal. IC specimens from rabbit eyes instilled with
PBS or LCEm (Figure 4D,E) showed an almost homogeneous
and regular cell layer, with flat and regular epithelial cells and
a normal nuclear:cytoplasmic ratio. A few lymphocytes were
scattered among the epithelial cells; however, there were no
obvious patches of PMN infiltration.
Figure 3. IVCM images of rabbit CALT
after instillations with different PG eye
drops. IVCM images of rabbit CALT at
H4  after  BAC+latanoprost  (A),  BAC
+travoprost  (B),  BAC+bimatoprost  (C),
PBS  (D),  or  LCEm  (E)  instillations.
Numerous  inflammatory  cells  were
observed infiltrating the periphery and
center of the CALT structure, especially
after the instillation of BAC+latanoprost.
LCEm  did  not  induce  any  obvious
inflammatory cell infiltration, as in the
PBS-instilled  eyes.  The  scale  bar
indicates  100  μm.  New  IVCM  scale
including CALT description shows the
following  toxicity  order  (F):  BAC
+latanoprost  >  BAC+travoprost  >  BAC
+bimatoprost  at  H4.  There  was  no
significant difference between the PBS
and  LCEm  groups  at  all  times.  The
asterisk indicates a p<0.0001 compared
with  BAC+latanoprost.  The  double
asterisk indicates a p<0.003 compared
with  BAC+latanoprost  and  the  sharp
indicates a p<0.0002 compared with BAC
+travoprost.
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1695Analysis of the IC morphology score at H4 (Figure 4F)
revealed  that  the  highest  IC  scores  were  found  in  BAC
+latanoprost- and  BAC+travoprost-instilled groups (p<0.0005
for  BAC+latanoprost;  and  p<0.01  for  BAC+travoprost  when
compared with either PBS- and LCEm-instilled groups). The
BAC+bimatoprost group had a moderately high IC score at H4,
which was significantly higher than those of the PBS- and
LCEm-instilled groups (p<0.05 for the two groups). For the
PBS- and LCEm-instilled groups, low scores were reported
with no statistical difference at H4. At D1, all groups had IC
scores that returned to low levels without any statistically
significant differences between them.
The impression cytology was also analyzed using FCM
for CD45 (panleukocyte marker)-positive cell expression. At
H4, the BAC+latanoprost-treated group induced 62.63±12.76%
of CD45-positive cells (p<0.05 when compared with the BAC
+travoprost-treated group and p<0.02 when compared with the
other three groups). The BAC+travoprost- and BAC+bimatoprost-
treated groups had 28.74±15.95% and 20.54±12.28% CD45-
positive  cells,  respectively  (Figure  5A).  In  PBS-instilled
rabbits, approximately 8.00±2.08% of the cell population was
CD45-positive,  and  LCEm  induced  only  7.39±1.83%  of
CD45-positive  cells.  There  was  no  significant  difference
between these two groups. These CD45-positive cells were
mostly inflammatory cells, as demonstrated by the cytospin
centrifugation for the BAC+latanoprost (Figure 5B) group.
DISCUSSION
Recent  in  vivo  studies  performed  in  NZW  rabbits  in  our
laboratory have demonstrated the role of cationic emulsions
Figure  4.  Conjunctival  impression
cytology  stained  by  cresyl  violet  and
impression  cytology  scale.  BAC
+Latanoprost  (A)  induced  numerous
polymorphonuclear inflammatory cells
as  islets  (red  circles).  BAC+Travoprost
(B)  showed  epithelial  damage  with
inflammatory  islets.  BAC+Bimatoprost
(C)  induced  slight  epithelial  cell
disorganization.  PBS  (D)  and  LCEm
(E) rabbit eyes presented almost normal
epithelial patterns without any obvious
inflammatory cell infiltration (original
size 40X). IC scale (F) showed that the
highest  toxicity  was  found  in  BAC
+latanoprost-,  BAC+travoprost-, and  BAC
+bimatoprost-treated eyes. LCEm- and
PBS-instilled groups were similar. The
asterisk indicates a p<0.0005 compared
with  BAC+latanoprost.  The  sharp
indicates a p<0.01 compared with BAC
+travoprost  and  the  filled  diamond
indicates a p<0.05 compared with BAC
+bimatoprost.
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1696in  reducing  ocular  cytotoxicity  induced  by  quaternary
ammonium  compound  (QAC)-containing  solutions  [19].
After establishing the optimal methodology and observation
time required for obtaining the best and maximal information
from  this  acute  repeated-instillations  model,  experiments
examining the effects of the new LCEm formulation were
performed. Repeated instillations of the LCEm formulation
onto the ocular surface of the rabbit did not induce any obvious
changes  of  the  ocular  surface  microstructures  and  the
expression pattern of inflammatory markers, which presented
similar  results  to  the  PBS-treated  group.  Our  data  are  in
accordance  with  previous  studies  concluding  that  BAC-
containing latanoprost, travoprost, and bimatoprost eye drops
were cytotoxic for the cornea/conjunctiva tissues, at levels
related to the concentration of BAC [6-9]. Conversely, other
in vitro or in vivo studies showed that two preservative-free
PG solutions (BAC-travoprost Z or BAC-tafluprost) did not induce
any ocular surface side effects, i.e., conjunctival cytotoxicity,
apoptosis, or necrosis [6,12]. BAC-free Travoprost Z showed
significantly less toxicity than BAC+latanoprost [26] in vitro,
with  no  detectable  loss  of  epithelial  tight  junctions  [27].
Bathing rabbit eyes for 3 min with BAC-travoprost Z did not
cause  corneal  epithelial  toxicity  reactions.  However,  eyes
treated with BAC+latanoprost induced superficial cell loss, as a
result of the presence of high concentrations (0.02%) of BAC
[28].  Once-daily  dosing  of  BAC-travoprost  Z  produced
significantly  fewer  corneal  changes  and  less  conjunctival
inflammation than BAC+latanoprost treatment did. In fact, the
changes  seen  with  BAC-travoprost  Z  were  similar  to  those
observed in eyes treated with artificial tears [29].
In this study, we were especially interested in cationic
emulsion. This new formulation offers a new strategy for
ocular drug delivery of active compounds designed for the
treatment  of  different  chronic  ocular  diseases,  such  as
glaucoma, dry eye, or allergy. As these diseases require long-
term  treatment,  eye  drops  preserving  the  sensitive  ocular
surface  are  actively  sought.  Herein,  we  demonstrated  the
safety of a newly developed cationic emulsion formulation
containing  latanoprost.  Latanoprost  in  cationic  emulsion
showed no obvious ocular toxicity after multiple instillations,
and was as well tolerated by the ocular surface as the negative
control. The positive charge of the cationic emulsion was
brought about by the very low concentration of CKC (0.005%)
trapped in the oil phase (oil droplets) of the nonpreserved
LCEm emulsion [16,17]. It has already been demonstrated
that cationic emulsions with 0.002% CKC were not toxic for
the ocular surface [19]. Moreover, compared with traditional
solutions,  the  emulsion  could  optimize  the  ocular  surface
homeostasis by its oily properties, since the emulsion alone
was developed as a tear substitute for dry eye symptoms
(Cationorm®,  Novagali  Pharma  SA).  Similar  lipidic
compounds have been proposed as tear substitutes with good
relief of patient symptoms and signs. Thus, this new LCEm
can  be  used  for  glaucoma  patients,  especially  for  those
suffering from ocular surface diseases such as dry eye or
allergy.
The  constant  and  direct  deleterious  influence  of
preservatives  in  the  cornea  and  conjunctiva  was  largely
studied in previous studies [5,6,9]. There are still debates
about the efficacy of drugs, with or without preservatives. In
animal  models  or  in  humans,  the  preservative-free
prostaglandin  has  shown  a  similar  penetration  and
pharmacokinetic  properties  than  preserved  prostaglandins
[30-32]. In the present study, we also examined whether the
instillation of certain eye drops influenced or altered the eye-
associated  immunologic  system.  Immunotoxicity  is  the
Figure  5.  Conjunctival  imprints
evaluated by flow cytometry for CD45-
positive cells after multiple instillations
at  H4,  and  assessed  after  cytospin
centrifugation.  The  inflammatory
marker  clearly  showed  the  highest
expression  in  BAC-containing  eye
drops (A). PBS- and LCEm- instilled
groups  had  only  a  basal  level  of
expression. CD45-positive cells (green)
after instillations of BAC+latanoprost (B)
were  viewed  after  propidium  iodide
staining  (red)  and  cytospin
centrifugation. The scale bar indicates
50 μm. The asterisk indicates a p<0.05
compared with BAC+latanoprost-instilled
group. The double asterisk indicates a
p<0.02 compared with BAC+latanoprost-
instilled group.
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1697discipline of toxicology studying the interactions between
xenobiotics  and  the  immune  system  resulting  in  adverse
effects [33]. Long-term exposure to toxic substances in a
repeated manner can interact with the ocular immune system.
While  immune  privilege,  including  anterior  chamber-
associated immune deviation, was found to be maintained
after  topical  BAC+latanoprost  applications,  through
observations  of  corneal  neovascularization  and  corneal
allograft survival in mice [34], we demonstrated here that
BAC-containing  eye  drops  can  nevertheless  stimulate  the
activation  of  the  CALT  follicle,  an  immunologic  defense
mechanism of the ocular surface, by inducing inflammatory
cell infiltration and lymphatic vessel circulations. CALT is
organized  both  diffusely  and  in  aggregates  or  follicles
(principally of lymphocytes) in the lamina propria [35], and
was mainly observed in the tarsal and orbital conjunctiva of
the upper and lower lids. In contrast to BAC-containing eye
LCEm, were safe for the rabbit ocular surface, showing no
activation of the CALT follicle structure, i.e., no obvious
inflammatory cell infiltration was detected, just as in the PBS-
instilled  rabbits.  Published  immunohistochemistry  studies
have confirmed that these follicles were rich in CD20-positive
B cells, accompanied by diffused CD3-positive T cells at their
periphery.  Apart  from  T/B  lymphocytes,  macrophages,
plasma, and dendritic cells (DCs) can be found [36]. The
CALT immunocytes participate in diverse functions, such as
antimicrobial  defense,  hypersensitivity  (allergy),  allograft
rejection, and immune tolerance mechanisms [35,36]. CALT
follicles  were  not  well  explored  in  previous  toxicological
studies due to their location and the lack of pertinent tools.
IVCM-CALT analysis could explore in vivo the inflammatory
cell trafficking, directly recording lymphocyte movements
after a drug-induced stimulation. We used the CALT follicle
structure to distinguish the subclinical toxicity of eye drops
more sensitively and accurately, and it could be an important
criterion to be considered for the IVCM toxicity scores. Cell
trafficking and signaling, chemo-attractive activities within
CALT follicles during immunotoxic phenomena, remain to be
elucidated.
Here,  we  emphasize  the  importance  of  analyzing  the
entire ocular surface structure when assessing a drug-induced
toxicity in vivo: the cornea, limbus, conjunctiva epithelium/
stroma,  as  well  as  the  CALT  follicles.  In  this  study,  we
especially improved our previously published IVCM score
[19]  by  including  the  analysis  of  CALT  structure,  thus
strengthening  the  sensitivity  of  the  conjunctival
inflammatory/toxic  reaction  evaluation.  The  three  scoring
systems quantify the drug-induced ocular surface alterations:
(1) the modified Draize test for clinical observation, (2) the
IVCM  scale  for  microstructural  images  of  the  cornea/
conjunctiva  (CALT)/limbus,  and  (3)  the  IC  scores  for
impression cytology morphology. With the development of
these ex vivo and in vivo quantified systems, we did not need
to sacrifice the animals at each time point to test the ocular
toxicity of a new drug, the same animal was examined over
the  entire  observation  period,  thus  limiting  individual
variations.
In conclusion, we improved and standardized a set of in
vivo and ex vivo tools to explore the ocular toxicity of new
drug formulations and confirmed the nontoxicity profile of a
new cationic emulsion containing PG analogues. This new
latanoprost  cationic  emulsion  could  be  proposed  for  the
treatment of glaucoma in the near future. The emulsion may
also improve the long-term compliance of patients with less
discomfort and reduced ocular toxicity, especially in patients
presenting dry eye symptoms.
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